Investigating HIV/AIDS Patients’ Immune Response to Hepatitis B Vaccination

Authors

  • Negin Esmaeilpour دانشگاه علوم پزشکی تهران- مرکز تحقیقات ایدز ایران- استادیار بیماری¬های عفونی
  • Nahid Mirzaei دانشگاه علوم پزشکی تهران- بیمارستان امام خمینی- گروه عفونی- متخصص بیماری¬های عفونی
  • Reza Chaman دانشگاه علوم پزشکی شاهرود- مرکز تحقیقات علوم رفتاری و اجتماعی در سلامت- استادیار اپیدمیولوژی
  • Mehrnaz Rasoulinejad دانشگاه علوم پزشکی تهران- مرکز تحقیقات ایدز ایران- استاد بیماری¬های عفونی
  • Mahboobeh Haji-Abdolbaghi دانشگاه علوم پزشکی تهران- مرکز تحقیقات ایدز ایران- استاد بیماری¬های عفونی
  • Maryam Roham دانشگاه علوم پزشکی تهران- بیمارستان امام خمینی- گروه عفونی- متخصص بیماری¬های عفونی
  • SeyedAhmad SeyedAlinaghi دانشگاه علوم پزشکی تهران - مرکز تحقیقات ایدز ایران- پزشک عمومی
  • Seyyed Mostafa Hosseini دانشگاه علوم پزشكي تهران- دانشکده بهداشت- گروه آمار و اپیدمیولوژی- دانشیار
  • Mazeyar Parsa دانشگاه علوم پزشکی تهران- مرکز تحقیقات ایدز ایران- استادیار بیماری¬های عفونی
  • Ladan Payvar- Mehr دانشگاه علوم پزشکی تهران - مرکز تحقیقات ایدز ایران- کارشناس ارشد پرستاری
  • Hamid Emadi-Koochak دانشگاه علوم پزشکی تهران- مرکز تحقیقات ایدز ایران- استادیار بیماری¬های عفونی

DOI:

https://doi.org/10.22100/jkh.v5i1.126

Keywords:

Vaccination, Hepatitis B, HIV/AIDs

Abstract

Introduction: Because of the increased risk of chronicity of hepatitis B in HIV infected patients, immunization against HBV is recommended in patients infected with human immune deficiency virus. This study aims at determining the factors which affect the response to HBV vaccination in Iranian HIV positive adults, compared with a healthy control group.

Methods: From April 2007 to May 2008, 50 HIV+ and 50 healthy control subjects who were seronegative for HBV received 3 doses of hepatitis B vaccine at 0, 1 and 3-month points. About 1-2 months after the last dose of vaccine, HBS antibodies were tested in the two groups. Persons were considered vaccine responders if their HBS antibody levels were greater than 10 mIU/ml.

Results: In the HIV+ group 40 cases (80%) were vaccine responder and in control group, 46(92%) people responded to vaccine .The difference between the two groups was not statistically significant (P=0.8). There were no significant relationships between age, gender, BMI, smoking, alcohol drinking and the method infection and HARRT treatment. In the HIV group vaccine response was associated with CD4 count level (P=0.03).

Conclusion: HIV infected patients are recommended to be HBV vaccinated at the regular doses and intervals. If CD4 count is less than 200/µl, HBS antibody should be tested in certain period for HIV+ individuals.

Author Biographies

  • Negin Esmaeilpour, دانشگاه علوم پزشکی تهران- مرکز تحقیقات ایدز ایران- استادیار بیماری¬های عفونی


  • Maryam Roham, دانشگاه علوم پزشکی تهران- بیمارستان امام خمینی- گروه عفونی- متخصص بیماری¬های عفونی


  • Mazeyar Parsa, دانشگاه علوم پزشکی تهران- مرکز تحقیقات ایدز ایران- استادیار بیماری¬های عفونی

References

Kozeiel MJ, SiddiquiA. Hepatitis B virus and hepatitis delta virus. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and

practice of infectious disease, 6th ed. Philadelphia: Elsevier Churchill Livingstone; 2005.p.1846-1891.

Taithumyanon P, Punnahitananda S, Praisuwanna P, Thisyakorn U, Ruxrungtham K. Antibody response to hepatitis B immunization in infants born to HIV-infected mothers. J Med Assoc Thai 2002; 85(3):277-282.

Rey D, Krantz V, Partisani M, Schmitt MP, Meyer P, Libbrecht E, et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV- infected patients.Effects on HIV-1 viral load.Vaccine 2000;18(13):1161-1165.

Fonseca MO, Pang LW, Cavalheiro NP, Barone AA, Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV infected adult patients comparing a standard dose to a double dose. Vaccine 2005; 23(22):2902-2908.

Wong EK, Bodsworth NJ, Slade MA, Mulhall BP, Donovan B. Response to hepatitis B vaccination in a primary care setting: influence of HIV infection, CD4+ lymphocyte count and vaccination schedule. Int J STD AIDS 1996; 7(7):490-4.

Bailey CL, Smith V, Sands M. Hepatitis B vaccine: a seven-year study of adherence to the immunization guidelines and efficacy in HIV-1- positive adults. int J Infect Dis 2008;12(6):e77-e83.

Gandhi RT, Wurcel A, Lee H, Mcgovern B, Shopis J, Geary M, et al. Response to hepatitis B vaccine in HIV-1 positive subjects Who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J infect Dis 2005; 191(9):1435-41.

Tedaldi EM, Baker RK, Moorman AC, Wood KC, Fuhrer J, McCabe RE, et al. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin infect Dis 2004; 38(10):1478-84.

Overton ET, Sungkanuparph S, Powderly WG, Seyfried W, Groger RK, Aberg JA. Undectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis 2005; 41(7):1045-8.

Aalei K, Mansoori D, Aalaei A. Immune response to HBV vaccination in HIV/AIDS patients of Kermanshah Province. Babol Med J 2005; 6(22):46-51.

Wang C, Tang J, Song W, Lobashevsky E, Wilson CM, Kaslow RA. HLA and cytokine gene polymorphisms are independenty associated with responses to hepatitis B vaccination. Hepatology 2004; 39(4):978-988.

Published

2010-08-11

Issue

Section

Original Article(s)

How to Cite

Investigating HIV/AIDS Patients’ Immune Response to Hepatitis B Vaccination. (2010). Knowledge and Health in Basic Medical Sciences, 5(1), 1-4. https://doi.org/10.22100/jkh.v5i1.126

Most read articles by the same author(s)

1 2 > >>